Paradigm Biopharmaceuticals Ltd has released a press release.
Paradigm EOFY Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- PAR reports successful ross river phase 2 clinical trial
- PAR reports consistent pain reduction in knee OA of patients
- PAR corrects afr article
- Successful Completion of Retail Entitlement Offer
- Paradigm Corporate Update - May 2019
Later from Paradigm Biopharmaceuticals
- Appendix 4C - quarterly
- Paradigm files first ind with US FDA
- PARs drug reduces cartilage degradation in subjects with OA
- Appendix 4E and 2019 Annual Report
- PAR Expanded Access IND Cleared by US FDA
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals